<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34855874</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>12</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>A model framework for projecting the prevalence and impact of Long-COVID in the UK.</ArticleTitle><Pagination><StartPage>e0260843</StartPage><MedlinePgn>e0260843</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0260843</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0260843</ELocationID><Abstract><AbstractText>The objective of this paper is to model lost Quality Adjusted Life Years (QALYs) from symptoms arising from COVID-19 disease in the UK population, including symptoms of 'long-COVID'. The scope includes QALYs lost to symptoms, but not deaths, due to acute COVID-19 and long-COVID. The prevalence of symptomatic COVID-19, encompassing acute symptoms and long-COVID symptoms, was modelled using a decay function. Permanent injury as a result of COVID-19 infection, was modelled as a fixed prevalence. Both parts were combined to calculate QALY loss due to COVID-19 symptoms. Assuming a 60% final attack rate for SARS-CoV-2 infection in the population, we modelled 299,730 QALYs lost within 1 year of infection (90% due to symptomatic COVID-19 and 10% permanent injury) and 557,764 QALYs lost within 10 years of infection (49% due to symptomatic COVID-19 and 51% due to permanent injury). The UK Government willingness-to-pay to avoid these QALY losses would be &#xa3;17.9 billion and &#xa3;32.2 billion, respectively. Additionally, 90,143 people were subject to permanent injury from COVID-19 (0.14% of the population). Given the ongoing development in information in this area, we present a model framework for calculating the health economic impacts of symptoms following SARS-CoV-2 infection. This model framework can aid in quantifying the adverse health impact of COVID-19, long-COVID and permanent injury following COVID-19 in society and assist the proactive management of risk posed to health. Further research is needed using standardised measures of patient reported outcomes relevant to long-COVID and applied at a population level.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Chris</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5914-8873</Identifier><AffiliationInfo><Affiliation>UCL Institute of Health Informatics, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luteijn</LastName><ForeName>Michiel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hannover Re UK Life branch, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Letton</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Crystallise, Basildon, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>Josephine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Optum International.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4967-7181</Identifier><AffiliationInfo><Affiliation>Lloyds Banking Group, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have read the journal&#x2019;s policy and have the following competing interests: SM and WL are employees of Crystallise Ltd, which provides consultancy services to the healthcare, insurance and pharmaceuticals industries. SM is an employee of Lloyds Banking Group, which provides banking, investments, insurance and pension products. ML is an employee of Hannover Re, which reinsures insurance and pension products. JR is an employee of Optum International, which provides healthcare and health insurance services. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>2</Day><Hour>17</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34855874</ArticleId><ArticleId IdType="pmc">PMC8639065</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0260843</ArticleId><ArticleId IdType="pii">PONE-D-21-16088</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Coronavirus disease (COVID-19) pandemic. 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">37184163</ArticleId></ArticleIdList></Reference><Reference><Citation>GOV.UK Coronavirus (COVID-19) in the UK. 2020.</Citation></Reference><Reference><Citation>NICE, SIGN, RCGP. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London, Edinburgh; 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al.. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2020. Dec;thoraxjnl-2020-216086. doi: 10.1136/thoraxjnl-2020-216086</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser E. Long term respiratory complications of covid-19. BMJ. 2020. Aug;m3001. doi: 10.1136/bmj.m3001</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3001</ArticleId><ArticleId IdType="pubmed">32747332</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamdar BB, Suri R, Suchyta MR, Digrande KF, Sherwood KD, Colantuoni E, et al.. Return to work after critical illness: a systematic review and meta-analysis. Thorax. 2020. Jan;75(1):17&#x2013;27. doi: 10.1136/thoraxjnl-2019-213803</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2019-213803</ArticleId><ArticleId IdType="pmc">PMC7418481</ArticleId><ArticleId IdType="pubmed">31704795</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;6736(20):1&#x2013;9. doi: 10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. The prevalence of long COVID symptoms and COVID-19 complications. 2020.</Citation></Reference><Reference><Citation>Herridge MS, Moss M, Hough CL, Hopkins RO, Rice TW, Bienvenu OJ, et al.. Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Care Med. 2016. May;42(5):725&#x2013;38. doi: 10.1007/s00134-016-4321-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-016-4321-8</ArticleId><ArticleId IdType="pubmed">27025938</ArticleId></ArticleIdList></Reference><Reference><Citation>Herridge MS, Tansey CM, Matt&#xe9; A, Tomlinson G, Diaz-Granados N, Cooper A, et al.. Functional Disability 5 Years after Acute Respiratory Distress Syndrome. N Engl J Med. 2011. Apr;364(14):1293&#x2013;304. doi: 10.1056/NEJMoa1011802</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1011802</ArticleId><ArticleId IdType="pubmed">21470008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed H, Patel K, Greenwood D, Halpin S, Lewthwaite P, Salawu A, et al.. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. J Rehabil Med. 2020. doi: 10.2340/16501977-2694</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/16501977-2694</ArticleId><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald S, Martin C, Bale S, Luteijn M, Sarkar R. Construction of a demand and capacity model for intensive care and hospital ward beds, and mortality from COVID-19. MedRxiv. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8076441</ArticleId><ArticleId IdType="pubmed">33906636</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs AH, Goldstein DA, Kirwin E, Meacock R, Pandya A, Vanness DJ, et al.. Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. Health Econ. 2021. Mar;30(3):699&#x2013;707. doi: 10.1002/hec.4208</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.4208</ArticleId><ArticleId IdType="pubmed">33368853</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al.. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021. Feb;93(2):1013&#x2013;22. doi: 10.1002/jmv.26368</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C, Murray B, Varsavsky T, Graham M, Penfold R, Bowyer R, et al.. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms 2 collected by the Covid Symptoms Study App. MedRxiv. 2020.</Citation></Reference><Reference><Citation>Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al.. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ. 2020;369(March):1&#x2013;12. doi: 10.1136/bmj.m1985</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1985</ArticleId><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference><Reference><Citation>ICNARC. ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland 24 December 2020. 2020.</Citation></Reference><Reference><Citation>COVID-19 Daily Deaths. england.nhs.uk.</Citation></Reference><Reference><Citation>ONS. Coronavirus (COVID-19) Infection Survey: antibody data for the UK, January 2021. 2021.</Citation></Reference><Reference><Citation>Marti J, Hall P, Hamilton P, Lamb S, McCabe C, Lall R, et al.. One-year resource utilisation, costs and quality of life in patients with acute respiratory distress syndrome (ARDS): Secondary analysis of a randomised controlled trial. J Intensive Care. 2016;4(1):1&#x2013;11. doi: 10.1186/s40560-016-0178-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-016-0178-8</ArticleId><ArticleId IdType="pmc">PMC4982209</ArticleId><ArticleId IdType="pubmed">27525106</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen MF, Szende A, Cabases J, Ramos-Go&#xf1;i JM, Vilagut G, K&#xf6;nig HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Heal Econ. 2019. Mar;20(2):205&#x2013;16. doi: 10.1007/s10198-018-0955-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10198-018-0955-5</ArticleId><ArticleId IdType="pmc">PMC6438939</ArticleId><ArticleId IdType="pubmed">29445941</ArticleId></ArticleIdList></Reference><Reference><Citation>HM Treasury. THE GREEN BOOK CENTRAL GOVERNMENT GUIDANCE ON APPRAISAL AND EVALUATION. London; 2020.</Citation></Reference><Reference><Citation>Basu A, Gandhay VJ. Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States. Value Heal. 2021. Mar. doi: 10.1016/j.jval.2020.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2020.11.013</ArticleId><ArticleId IdType="pmc">PMC7938736</ArticleId><ArticleId IdType="pubmed">33933231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophuis RH, Olij BF, Polinder S, Haagsma JA. Prevalence of post-traumatic stress disorder, acute stress disorder and depression following violence related injury treated at the emergency department: a systematic review. BMC Psychiatry. 2018. Dec;18(1):311. doi: 10.1186/s12888-018-1890-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-018-1890-9</ArticleId><ArticleId IdType="pmc">PMC6156976</ArticleId><ArticleId IdType="pubmed">30253782</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson KF, Kehle SM, Meis LA, Greer N, MacDonald R, Rutks I, et al.. Prevalence, Assessment, and Treatment of Mild Traumatic Brain Injury and Posttraumatic Stress Disorder. J Head Trauma Rehabil. 2011;26(2):103&#x2013;15. doi: 10.1097/HTR.0b013e3181e50ef1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HTR.0b013e3181e50ef1</ArticleId><ArticleId IdType="pubmed">20631631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis G, Wessely S. The epidemiology of fatigue: more questions than answers. J Epidemiol Community Heal. 1992. Apr;46(2):92&#x2013;7. doi: 10.1136/jech.46.2.92</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech.46.2.92</ArticleId><ArticleId IdType="pmc">PMC1059513</ArticleId><ArticleId IdType="pubmed">1583440</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlejohns P, Ebrahim S, Anderson R. Prevalence and diagnosis of chronic respiratory symptoms in adults. Br Med J. 1989;298(6687):1556&#x2013;60. doi: 10.1136/bmj.298.6687.1556</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.298.6687.1556</ArticleId><ArticleId IdType="pmc">PMC1836795</ArticleId><ArticleId IdType="pubmed">2503115</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler DA, Wells CK. Evaluation of Clinical Methods for Rating Dyspnea. Chest. 1988. Mar;93(3):580&#x2013;6. doi: 10.1378/chest.93.3.580</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.93.3.580</ArticleId><ArticleId IdType="pubmed">3342669</ArticleId></ArticleIdList></Reference><Reference><Citation>Zala D, Mosweu I, Critchlow S, Romeo R, McCrone P. Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom. Value Heal. 2020. Nov;23(11):1432&#x2013;7. doi: 10.1016/j.jval.2020.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2020.07.001</ArticleId><ArticleId IdType="pmc">PMC7833705</ArticleId><ArticleId IdType="pubmed">33127013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al.. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020. Dec;396(10267):1979&#x2013;93. doi: 10.1016/S0140-6736(20)32466-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32466-1</ArticleId><ArticleId IdType="pmc">PMC7674972</ArticleId><ArticleId IdType="pubmed">33220855</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021. Feb;384(5):403&#x2013;16. doi: 10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan NA, Attree E, Blair JM, Bogaert D, Bowen M-A, Boyle J, et al.. From doctors as patients: a manifesto for tackling persisting symptoms of covid-19. BMJ. 2020. Sep;m3565. doi: 10.1136/bmj.m3565</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3565</ArticleId><ArticleId IdType="pubmed">32933949</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>